About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2014 (2014), Article ID 436985, 7 pages
http://dx.doi.org/10.1155/2014/436985
Research Article

Prognostic and Predictive Value of CpG Island Methylator Phenotype in Patients with Locally Advanced Nonmetastatic Sporadic Colorectal Cancer

1Department of Colorectal Surgery, Fudan University, 270 Dong An Road, Shanghai 200032, China
2Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong An Road, Shanghai 200032, China

Received 11 November 2013; Accepted 17 December 2013; Published 14 January 2014

Academic Editor: Qi Li

Copyright © 2014 Yuwei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013.
  2. M. Toyota, N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin, and J.-P. J. Issa, “CpG island methylator phenotype in colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 15, pp. 8681–8686, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Hawkins, M. Norrie, K. Cheong et al., “CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability,” Gastroenterology, vol. 122, no. 5, pp. 1376–1387, 2002. View at Scopus
  4. D. J. Weisenberger, K. D. Siegmund, M. Campan et al., “CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer,” Nature Genetics, vol. 38, no. 7, pp. 787–793, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Goel, T. Nagasaka, C. N. Arnold et al., “The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer,” Gastroenterology, vol. 132, no. 1, pp. 127–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. M. Jubb, S. M. Bell, and P. Quirke, “Methylation and colorectal cancer,” Journal of Pathology, vol. 195, no. 1, pp. 111–134, 2001.
  7. S. B. Edge and C. C. Compton, “The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,” Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Cai, Y. Xu, H. Lu et al., “Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers,” International Journal of Colorectal Disease, vol. 23, no. 4, pp. 365–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. L. A. E. Hughes, C. A. J. Khalid-de Bakker, K. M. Smits et al., “The CpG island methylator phenotype in colorectal cancer: progress and problems,” Biochimica et Biophysica Acta, vol. 1825, no. 1, pp. 77–85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Jass, “Classification of colorectal cancer based on correlation of clinical, morphological and molecular features,” Histopathology, vol. 50, no. 1, pp. 113–130, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. W. S. Samowitz, H. Albertsen, J. Herrick et al., “Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer,” Gastroenterology, vol. 129, no. 3, pp. 837–845, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. L. Ward, K. Cheong, S.-L. Ku, A. Meagher, T. O'Connor, and N. J. Hawkins, “Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3729–3736, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Lee, N.-Y. Cho, E. J. Yoo, J. H. Kim, and G. H. Kang, “CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CPG island methylator phenotype marker panels,” Archives of Pathology and Laboratory Medicine, vol. 132, no. 10, pp. 1657–1665, 2008. View at Scopus
  14. L. Barault, C. Charon-Barra, V. Jooste et al., “Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases,” Cancer Research, vol. 68, no. 20, pp. 8541–8546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Lee, N.-Y. Cho, M. Choi, E. J. Yoo, J.-H. Kim, and G. H. Kang, “Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation,” Pathology International, vol. 58, no. 2, pp. 104–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. H. Kim, S. H. Shin, H. J. Kwon, N. Y. Cho, and G. H. Kang, “Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers,” Virchows Archiv, vol. 455, no. 6, pp. 485–494, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Ogino, K. Nosho, G. J. Kirkner et al., “CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer,” Gut, vol. 58, no. 1, pp. 90–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Ogino, J. A. Meyerhardt, T. Kawasaki et al., “CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma,” Virchows Archiv, vol. 450, no. 5, pp. 529–537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Shen, P. J. Catalano, A. B. Benson III, P. O'Dwyer, S. R. Hamilton, and J.-P. J. Issa, “Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy,” Clinical Cancer Research, vol. 13, no. 20, pp. 6093–6098, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Jover, T. Nguyen, L. Prezcarbonell et al., “5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer,” Gastroenterology, vol. 140, no. 4, pp. 1174–1181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Van Rijnsoever, H. Elsaleh, D. Joseph, K. McCaul, and B. Iacopetta, “CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer,” Clinical Cancer Research, vol. 9, no. 8, pp. 2898–2903, 2003. View at Scopus
  22. B.-H. Min, J. M. Bae, E. J. Lee et al., “The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy,” BMC Cancer, vol. 11, article 344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Rashid, L. Shen, J. S. Morris, J.-P. J. Issa, and S. R. Hamilton, “CpG island methylation in colorectal adenomas,” American Journal of Pathology, vol. 159, no. 3, pp. 1129–1135, 2001. View at Scopus
  24. M. Toyota, N. Ahuja, H. Suzuki et al., “Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype,” Cancer Research, vol. 59, no. 21, pp. 5438–5442, 1999. View at Scopus
  25. H. Yamamoto, Y. Min, F. Itoh et al., “Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability,” Genes Chromosomes and Cancer, vol. 33, no. 3, pp. 322–325, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Kim, Y. H. Kim, S. E. Kim, N.-G. Kim, S. H. Noh, and H. Kim, “Concerted promoter hypermethylation of hMLHI, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability,” Journal of Pathology, vol. 200, no. 1, pp. 23–31, 2003. View at Publisher · View at Google Scholar · View at Scopus